Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 24 | 2013 | 4980 | 0.390 |
Why?
|
| Survivors | 3 | 2022 | 1024 | 0.380 |
Why?
|
| Sarcoma, Ewing | 10 | 1996 | 426 | 0.370 |
Why?
|
| Ependymoma | 8 | 2013 | 269 | 0.290 |
Why?
|
| Soft Tissue Neoplasms | 8 | 1996 | 917 | 0.280 |
Why?
|
| Sarcoma | 11 | 1998 | 1839 | 0.270 |
Why?
|
| Bone Neoplasms | 11 | 1996 | 2667 | 0.260 |
Why?
|
| Rhabdomyosarcoma | 10 | 1996 | 342 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2006 | 16598 | 0.230 |
Why?
|
| Work Schedule Tolerance | 1 | 2003 | 48 | 0.230 |
Why?
|
| Cyclophosphamide | 6 | 2005 | 3231 | 0.210 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2005 | 343 | 0.210 |
Why?
|
| Child, Preschool | 38 | 2014 | 16919 | 0.190 |
Why?
|
| Burnout, Professional | 1 | 2003 | 226 | 0.170 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 268 | 0.170 |
Why?
|
| Thiotepa | 2 | 1995 | 132 | 0.150 |
Why?
|
| Kidney Tubules | 6 | 1987 | 145 | 0.150 |
Why?
|
| Internet | 2 | 2022 | 697 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2003 | 1042 | 0.140 |
Why?
|
| Agranulocytosis | 1 | 1996 | 83 | 0.140 |
Why?
|
| Razoxane | 1 | 1996 | 22 | 0.130 |
Why?
|
| Child | 37 | 2022 | 30343 | 0.130 |
Why?
|
| Neoplasms | 8 | 2022 | 15852 | 0.120 |
Why?
|
| Cardiovascular Agents | 1 | 1996 | 117 | 0.120 |
Why?
|
| Doxorubicin | 5 | 1996 | 3138 | 0.120 |
Why?
|
| Infant | 25 | 2013 | 13867 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 426 | 0.120 |
Why?
|
| Thrombocytopenia | 2 | 1996 | 871 | 0.110 |
Why?
|
| Combined Modality Therapy | 21 | 1999 | 9040 | 0.110 |
Why?
|
| Ifosfamide | 6 | 1996 | 357 | 0.110 |
Why?
|
| Whole-Body Irradiation | 1 | 1993 | 324 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1996 | 744 | 0.100 |
Why?
|
| Antineoplastic Agents | 7 | 2013 | 14679 | 0.100 |
Why?
|
| Medulloblastoma | 5 | 2013 | 586 | 0.100 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 4 | 1996 | 36 | 0.100 |
Why?
|
| Education, Medical, Graduate | 2 | 2010 | 696 | 0.090 |
Why?
|
| Cancer Survivors | 1 | 2018 | 741 | 0.090 |
Why?
|
| Adolescent | 29 | 2006 | 32508 | 0.080 |
Why?
|
| Heart | 1 | 1996 | 1211 | 0.080 |
Why?
|
| Schools, Medical | 1 | 2010 | 132 | 0.080 |
Why?
|
| Cisplatin | 5 | 1995 | 2493 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 2 | 1999 | 1773 | 0.080 |
Why?
|
| Humans | 63 | 2022 | 270825 | 0.080 |
Why?
|
| Leadership | 1 | 2010 | 261 | 0.070 |
Why?
|
| Rhabdoid Tumor | 2 | 1997 | 111 | 0.070 |
Why?
|
| Male | 36 | 2013 | 128398 | 0.070 |
Why?
|
| Glioma | 8 | 2006 | 1969 | 0.060 |
Why?
|
| Pilot Projects | 4 | 1999 | 2847 | 0.060 |
Why?
|
| Female | 35 | 2013 | 148456 | 0.060 |
Why?
|
| Etoposide | 3 | 1996 | 905 | 0.060 |
Why?
|
| Adult | 26 | 2006 | 81540 | 0.060 |
Why?
|
| Injections, Spinal | 1 | 2005 | 276 | 0.060 |
Why?
|
| Switzerland | 1 | 2003 | 25 | 0.060 |
Why?
|
| Headache | 1 | 2005 | 174 | 0.060 |
Why?
|
| Misonidazole | 1 | 1983 | 11 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 3 | 1998 | 1379 | 0.060 |
Why?
|
| Affect | 1 | 2005 | 306 | 0.050 |
Why?
|
| Morphine | 1 | 2005 | 332 | 0.050 |
Why?
|
| Osteosarcoma | 6 | 1995 | 948 | 0.050 |
Why?
|
| Nitroimidazoles | 1 | 1983 | 107 | 0.050 |
Why?
|
| Vincristine | 3 | 1996 | 1572 | 0.050 |
Why?
|
| Workload | 1 | 2003 | 198 | 0.050 |
Why?
|
| Survivorship | 1 | 2022 | 117 | 0.050 |
Why?
|
| Survival Analysis | 8 | 2006 | 9304 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 1322 | 0.050 |
Why?
|
| Drug Administration Schedule | 6 | 1998 | 3538 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 626 | 0.050 |
Why?
|
| Chromosome Aberrations | 3 | 1995 | 2022 | 0.040 |
Why?
|
| Glioblastoma | 3 | 1996 | 1777 | 0.040 |
Why?
|
| Mesna | 3 | 1989 | 67 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2005 | 1506 | 0.040 |
Why?
|
| Pinealoma | 2 | 1999 | 52 | 0.040 |
Why?
|
| Lung Neoplasms | 4 | 1998 | 11775 | 0.040 |
Why?
|
| Mercaptoethanol | 2 | 1989 | 16 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 1999 | 2266 | 0.040 |
Why?
|
| Disease-Free Survival | 4 | 2006 | 10250 | 0.040 |
Why?
|
| Carrier Proteins | 4 | 2006 | 2123 | 0.040 |
Why?
|
| Neurilemmoma | 4 | 1993 | 134 | 0.040 |
Why?
|
| Kidney Diseases | 3 | 1987 | 726 | 0.040 |
Why?
|
| Cranial Irradiation | 2 | 1999 | 322 | 0.040 |
Why?
|
| Acetylglucosaminidase | 5 | 1987 | 19 | 0.030 |
Why?
|
| Pain | 1 | 2005 | 1695 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2018 | 306 | 0.030 |
Why?
|
| Transaminases | 1 | 1996 | 82 | 0.030 |
Why?
|
| Pineal Gland | 1 | 1995 | 49 | 0.030 |
Why?
|
| Age Factors | 1 | 2005 | 5485 | 0.030 |
Why?
|
| Postoperative Period | 3 | 1998 | 671 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1996 | 596 | 0.030 |
Why?
|
| Survival Rate | 7 | 1999 | 12515 | 0.030 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 1995 | 32 | 0.030 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 1995 | 44 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2005 | 1456 | 0.030 |
Why?
|
| Aminopeptidases | 4 | 1987 | 33 | 0.030 |
Why?
|
| Follow-Up Studies | 8 | 1998 | 15239 | 0.030 |
Why?
|
| CD13 Antigens | 4 | 1987 | 43 | 0.030 |
Why?
|
| Drug Evaluation | 6 | 1992 | 435 | 0.030 |
Why?
|
| Ganglioglioma | 1 | 1994 | 41 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1996 | 401 | 0.030 |
Why?
|
| Nitrosourea Compounds | 2 | 1983 | 14 | 0.030 |
Why?
|
| Ethylnitrosourea | 2 | 1983 | 20 | 0.030 |
Why?
|
| Foot | 1 | 1994 | 108 | 0.030 |
Why?
|
| Astrocytoma | 3 | 1993 | 334 | 0.030 |
Why?
|
| Camptothecin | 1 | 1996 | 538 | 0.030 |
Why?
|
| Proteinuria | 4 | 1987 | 166 | 0.030 |
Why?
|
| Karyotyping | 3 | 1995 | 1064 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1995 | 310 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 1994 | 311 | 0.030 |
Why?
|
| Hand | 1 | 1994 | 175 | 0.030 |
Why?
|
| Supratentorial Neoplasms | 1 | 2013 | 79 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2018 | 643 | 0.030 |
Why?
|
| Stroke Volume | 1 | 1996 | 578 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 1991 | 316 | 0.030 |
Why?
|
| Nevus, Pigmented | 1 | 1993 | 115 | 0.030 |
Why?
|
| Neoplasms, Experimental | 4 | 1983 | 791 | 0.030 |
Why?
|
| Cholecystokinin | 1 | 1992 | 51 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2003 | 1431 | 0.030 |
Why?
|
| Prospective Studies | 5 | 1996 | 13361 | 0.030 |
Why?
|
| Meglumine | 1 | 1992 | 21 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1992 | 50 | 0.030 |
Why?
|
| Neutropenia | 1 | 1996 | 1001 | 0.020 |
Why?
|
| Blood-Brain Barrier | 2 | 1983 | 247 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 3 | 1983 | 513 | 0.020 |
Why?
|
| Topotecan | 2 | 2006 | 248 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 1992 | 173 | 0.020 |
Why?
|
| Radiotherapy Dosage | 4 | 1996 | 4003 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1993 | 299 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1992 | 209 | 0.020 |
Why?
|
| Osteotomy | 1 | 1991 | 103 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1971 | 289 | 0.020 |
Why?
|
| Liver Neoplasms | 2 | 1987 | 4789 | 0.020 |
Why?
|
| Thoracotomy | 1 | 1992 | 218 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1992 | 634 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1995 | 1053 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 1995 | 863 | 0.020 |
Why?
|
| Extremities | 1 | 1991 | 307 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1994 | 1107 | 0.020 |
Why?
|
| Prognosis | 8 | 1998 | 22452 | 0.020 |
Why?
|
| Professional Competence | 1 | 2010 | 135 | 0.020 |
Why?
|
| Heart Rate | 1 | 1971 | 762 | 0.020 |
Why?
|
| Treatment Outcome | 5 | 2013 | 33821 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2421 | 0.020 |
Why?
|
| Fibroma | 1 | 1987 | 87 | 0.020 |
Why?
|
| Methotrexate | 2 | 1990 | 1026 | 0.020 |
Why?
|
| Creatinine | 2 | 1987 | 545 | 0.020 |
Why?
|
| Autoradiography | 2 | 1983 | 158 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 1999 | 8566 | 0.020 |
Why?
|
| Thymectomy | 1 | 1987 | 80 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1992 | 549 | 0.020 |
Why?
|
| Aging | 1 | 1995 | 1576 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1983 | 238 | 0.020 |
Why?
|
| Hospitalization | 1 | 1996 | 2192 | 0.020 |
Why?
|
| Procarbazine | 1 | 2006 | 71 | 0.020 |
Why?
|
| Blood | 1 | 1987 | 171 | 0.020 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 1999 | 102 | 0.020 |
Why?
|
| Nervous System | 1 | 1987 | 183 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 733 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1987 | 570 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 1993 | 7782 | 0.020 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2006 | 91 | 0.020 |
Why?
|
| Regional Blood Flow | 2 | 1983 | 286 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2006 | 198 | 0.020 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2006 | 172 | 0.020 |
Why?
|
| Chromosomes, Human, 1-3 | 1 | 1985 | 4 | 0.020 |
Why?
|
| Child Development | 1 | 1988 | 267 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 1994 | 3349 | 0.020 |
Why?
|
| Contrast Media | 1 | 1992 | 1510 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 1983 | 948 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 1987 | 703 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1987 | 1567 | 0.010 |
Why?
|
| Carcinoma | 1 | 1995 | 2627 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 3169 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1992 | 5184 | 0.010 |
Why?
|
| Heart Failure | 1 | 1996 | 2496 | 0.010 |
Why?
|
| Cell Division | 1 | 1987 | 2716 | 0.010 |
Why?
|
| Rats | 4 | 1983 | 6639 | 0.010 |
Why?
|
| Treatment Failure | 2 | 1995 | 1432 | 0.010 |
Why?
|
| Life Tables | 2 | 1991 | 122 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1987 | 1547 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1996 | 3859 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1995 | 5103 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 1993 | 7922 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1987 | 1961 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1996 | 1437 | 0.010 |
Why?
|
| Lung | 1 | 1992 | 3268 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1987 | 3086 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2006 | 1740 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 1467 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 1999 | 3972 | 0.010 |
Why?
|
| Neoplasm Metastasis | 2 | 1986 | 5325 | 0.010 |
Why?
|
| Aneuploidy | 2 | 1992 | 377 | 0.010 |
Why?
|
| Proportional Hazards Models | 2 | 1998 | 5084 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 1993 | 10350 | 0.010 |
Why?
|
| Growth Disorders | 1 | 1999 | 224 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1999 | 565 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1993 | 4835 | 0.010 |
Why?
|
| Dipeptidyl Peptidase 4 | 2 | 1986 | 57 | 0.010 |
Why?
|
| Age Distribution | 1 | 1998 | 728 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1992 | 9083 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2010 | 39679 | 0.010 |
Why?
|
| Brain Stem | 1 | 1996 | 185 | 0.010 |
Why?
|
| Drug Synergism | 2 | 1990 | 1369 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1997 | 835 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1996 | 749 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1992 | 5834 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 7810 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 3460 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 1995 | 192 | 0.010 |
Why?
|
| Incidence | 2 | 1996 | 5837 | 0.010 |
Why?
|
| Dacarbazine | 2 | 1987 | 505 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1995 | 297 | 0.010 |
Why?
|
| Recurrence | 2 | 1994 | 4882 | 0.010 |
Why?
|
| Animals | 5 | 1987 | 62801 | 0.010 |
Why?
|
| Gliosarcoma | 1 | 1994 | 33 | 0.010 |
Why?
|
| Fluorouracil | 2 | 1990 | 1985 | 0.010 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 1994 | 64 | 0.010 |
Why?
|
| Aminoisobutyric Acids | 2 | 1983 | 11 | 0.010 |
Why?
|
| Reoperation | 1 | 1998 | 1387 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1994 | 141 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1994 | 174 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1983 | 483 | 0.010 |
Why?
|
| Time Factors | 3 | 1994 | 13103 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1994 | 485 | 0.010 |
Why?
|
| Oligodendroglioma | 2 | 1983 | 105 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 1994 | 237 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1994 | 615 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1992 | 145 | 0.010 |
Why?
|
| Myelography | 1 | 1992 | 21 | 0.010 |
Why?
|
| Neoplasm Staging | 3 | 1994 | 13977 | 0.010 |
Why?
|
| Risk | 1 | 1996 | 1913 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1994 | 1214 | 0.010 |
Why?
|
| Craniotomy | 1 | 1994 | 306 | 0.010 |
Why?
|
| Skin Temperature | 1 | 1971 | 34 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1992 | 728 | 0.010 |
Why?
|
| Mitosis | 1 | 1994 | 690 | 0.010 |
Why?
|
| Meningioma | 1 | 1994 | 307 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 1991 | 256 | 0.010 |
Why?
|
| Fetal Heart | 1 | 1971 | 113 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 1999 | 2118 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1994 | 1730 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1992 | 811 | 0.010 |
Why?
|
| Meningeal Neoplasms | 1 | 1994 | 473 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 1744 | 0.010 |
Why?
|
| Leucovorin | 1 | 1990 | 343 | 0.010 |
Why?
|
| Oncogenes | 1 | 1992 | 700 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1992 | 1585 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 594 | 0.000 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1995 | 1068 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1991 | 1566 | 0.000 |
Why?
|
| Cerebellar Neoplasms | 1 | 1993 | 486 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1987 | 163 | 0.000 |
Why?
|
| Immunochemistry | 1 | 1986 | 64 | 0.000 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1987 | 26 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1986 | 211 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1995 | 4980 | 0.000 |
Why?
|
| Urologic Diseases | 1 | 1987 | 83 | 0.000 |
Why?
|
| Brain | 2 | 1994 | 4245 | 0.000 |
Why?
|
| Risk Assessment | 1 | 1998 | 6828 | 0.000 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 1985 | 13 | 0.000 |
Why?
|
| Mice | 1 | 1987 | 36026 | 0.000 |
Why?
|
| Hematologic Diseases | 1 | 1987 | 255 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1993 | 4067 | 0.000 |
Why?
|
| Clone Cells | 1 | 1985 | 592 | 0.000 |
Why?
|
| Methylnitrosourea | 1 | 1983 | 51 | 0.000 |
Why?
|
| Choroid Plexus | 1 | 1983 | 37 | 0.000 |
Why?
|
| Subarachnoid Space | 1 | 1983 | 38 | 0.000 |
Why?
|
| Carboplatin | 1 | 1987 | 879 | 0.000 |
Why?
|
| Capillary Permeability | 1 | 1983 | 115 | 0.000 |
Why?
|
| Wilms Tumor | 1 | 1985 | 297 | 0.000 |
Why?
|
| Remission Induction | 1 | 1989 | 3645 | 0.000 |
Why?
|
| Nervous System Diseases | 1 | 1987 | 520 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1992 | 6484 | 0.000 |
Why?
|
| Biological Transport | 1 | 1983 | 647 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1983 | 543 | 0.000 |
Why?
|
| Acute Disease | 1 | 1987 | 2512 | 0.000 |
Why?
|
| Chromosome Deletion | 1 | 1985 | 1054 | 0.000 |
Why?
|
| Pregnancy | 2 | 1983 | 8034 | 0.000 |
Why?
|
| Kinetics | 1 | 1983 | 2246 | 0.000 |
Why?
|
| Lymphoma | 1 | 1987 | 1514 | 0.000 |
Why?
|
| Hippocampus | 1 | 1983 | 973 | 0.000 |
Why?
|
| Neoplastic Stem Cells | 1 | 1985 | 1469 | 0.000 |
Why?
|
| Biomarkers, Tumor | 1 | 1994 | 10698 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1985 | 2161 | 0.000 |
Why?
|
| Head and Neck Neoplasms | 1 | 1987 | 4124 | 0.000 |
Why?
|
| Middle Aged | 1 | 1994 | 90030 | 0.000 |
Why?
|